G5 Partners currently advises Health2047, a new innovation enterprise whose mission is to transform the healthcare industry by developing and commercializing solutions for data liquidity, chronic care, productivity, and payments. This unique business model is designed to yield market impact, social impact, and financial return by leveraging strategic partners’ expertise and investment capabilities. Health2047 enjoys unique access to the subject matter expertise of the AMA’s staff, as well as the knowledge gained by the AMA’s convening of the House of Medicine (185 physician societies – state and specialty – representing essentially all physicians in the U.S.) and its 230,000+ direct physician and medical student members. In Q3 2015, Health2047’s board named G5P Managing Partner Doug Given its founding CEO. Given the immense societal impact of this particular business opportunity, Doug committed to operationally guide Health2047. In Q2 2018, Doug serves as Managing Partner at Health2047 Capital Partners, aligning his role with the AMA and Health2047 by continuing on the board and leading the board’s strategy committee.
Polishing a Real Gem
G5 Partners recognized Arrowhead Pharmaceuticals (ARWR) for its potential as a therapeutic iRNA investment on first encounter. Arrowhead was the first to reach human trials with iRNA therapeutics and publish, yet issues around drug delivery loomed large. G5Partners helped Arrowhead identify and acquire outstanding assets from Roche and Norvatis to advance its delivery platform and therapeutic area reach, helping guide the company from research into clinical development. The company is now advancing clinical trials in hepatitis B and proceeding with a first-in-human study of ARO-HBV, which is being developed as a potentially curative gene-silencing therapy for patients with chronic hepatitis B virus (HBV) infection, thus leading the industry in meeting this significant public health need.